Antibody Firm KaloBios Enters IPO Queue, Aims to Raise $60M
By Marie Powers
Monday, October 8, 2012
On Friday, monoclonal antibody (mAb) developer KaloBios Pharmaceuticals Inc. filed a registration statement with the SEC for a proposed initial public offering (IPO), indicating a proposed maximum offering price of $60 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.